http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111658651-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
filingDate 2020-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2021-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-111658651-B
titleOfInvention Application of CQMU151 in preparing medicament for treating Th17 cell-mediated autoimmune disease
abstract The invention relates to application of 1H-benzo [ d ] imidazole-2-yl) methyl) -3- (morpholinosulfonyl) benzamide in preparation of a medicament for treating Th17 cell-mediated autoimmune disease. The invention obtains the compound by screening from the Chembridge compound library, and experiments show that: the compound has the function of inhibiting the differentiation of Th17 cells in vitro; can inhibit the differentiation of Th17 cells and the generation of IL-17 in vivo, and relieve the clinical symptoms of autoimmune diseases such as Th17 cell-mediated Experimental Autoimmune Uveitis (EAU), Experimental Autoimmune Encephalomyelitis (EAE), type 1 diabetes and the like, and has good application prospect.
priorityDate 2020-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106232582-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012064744-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013178362-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108430973-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3192791-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013036912-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020011147-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507055
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID154496482
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433322164
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452041512
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323660
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23692753
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2724385
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13073352

Total number of triples: 36.